- Home
- HIVE vs GERN Comparison
HIVE vs GERN Comparison
Compare HIVE & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIVE | GERN |
|---|---|---|
| Founded | 1987 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 647.3M | 753.3M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | HIVE | GERN |
|---|---|---|
| Price | $3.41 | $1.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $8.33 | $3.00 |
| AVG Volume (30 Days) | ★ 11.3M | 7.7M |
| Earning Date | 02-10-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $193,254,000.00 | $183,403,000.00 |
| Revenue This Year | $185.64 | $147.42 |
| Revenue Next Year | $44.55 | $37.07 |
| P/E Ratio | $17.40 | ★ N/A |
| Revenue Growth | 57.09 | ★ 522.13 |
| 52 Week Low | $1.26 | $1.04 |
| 52 Week High | $7.84 | $3.12 |
Technical Indicators
Market Signals| Indicator | HIVE | GERN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.74 |
| Support Level | N/A | $1.28 |
| Resistance Level | N/A | $1.48 |
| Average True Range (ATR) | 0.00 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 9.37 |
Price Performance
Historical ComparisonAbout HIVE HIVE Digital Technologies Ltd.
HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.